Joshua M. Eizen, who holds the dual roles of Chief Operating Officer and Chief Legal Officer at AN2 Therapeutics, Inc. (NASDAQ: ANTX), executed a transaction involving the sale of 5,945 shares of the company's common stock on July 8, 2026. The shares were disposed of at a price point of $4.172 per share, resulting in a total transaction value of $24,802. This movement in the stock is set against a backdrop of considerable price action for ANTX; the stock is currently trading at $4.50. This current price level reflects a dramatic 321% return over the past twelve months, yet it remains 35% below the 52-week high of $6.91.
The nature of this sale is structural rather than discretionary. The transaction represents shares that were disposed of specifically to satisfy tax withholding obligations. These obligations arose from the vesting of Restricted Stock Units (RSUs) that occurred on July 1, 2026. Following this transaction, Mr. Eizen's direct holding in AN2 Therapeutics common stock stands at 206,554 shares. This remaining balance is composed of several vesting schedules contingent on his continuous service. These include 30,000 RSUs vesting annually over four years from January 1, 2024; 31,500 RSUs vesting annually over four years from November 4, 2024; 58,500 RSUs vesting annually over four years from January 1, 2025; and 50,000 RSUs vesting annually over four years from January 1, 2026. The reported total also incorporates the purchase of 5,000 shares under the company’s 2022 Employee Stock Purchase Plan on March 31, 2026.
From a balance sheet perspective, AN2 Therapeutics presents a position of liquidity strength. The company maintains more cash than debt, with liquid assets exceeding short-term obligations by a substantial margin, according to InvestingPro analysis. However, the firm is not yet profitable, and analysts do not anticipate profitability for the current year. InvestingPro data suggests the stock may be overvalued at current levels, with 7 additional ProTips available to subscribers.
In parallel with executive compensation events, AN2 Therapeutics has announced promising results from studies on their oral treatment for chronic Chagas disease. According to the company’s press release, the treatment, designated as AN2-502998, achieved complete parasite elimination in nonhuman primates infected with Trypanosoma cruzi. This outcome was sustained for four months following the completion of a 28-day treatment period. These findings are significant as they align with the target exposure levels intended for human use. The results mark a positive development for AN2 Therapeutics in the field of infectious disease treatment. Such advancements are crucial for the company as they continue to focus on developing effective treatments for neglected tropical diseases.